Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/24/2022
Summary
Zoon Kathryn C, a director of Emergent BioSolutions Inc., reports on this Form 4 the sale of 1,996 shares of common stock at $35.53 on 05/24/2022. The explanation of responses says all transactions listed were made by the Reporting Person under a trading plan intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. After the sale, 12,381 shares were owned directly. The remarks show /s/ S. Scott Lieberman, Attorney-in-fact, dated 05/25/2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“Form 4: Emergent BioSolutions Inc. (EBS), Zoon Kathryn C, transaction 05/24/2022.”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ebs-4-filed2022-05-25-0001367644-22-000077-04e32eef58/
, SHA-256 bca7750f0ee904cfec54decbd443189a338f31ae5c044a32f7040a7bc7e0bbca.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * Zoon Kathryn C (Last) (First) (Middle) 400 PROFESSIONAL DRIVE (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | Zoon Kathryn C | (Last) | (First) | (Middle) | 400 PROFESSIONAL DRIVE | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) | X | Director | 10% Owner | Officer (give title below) | Other (specify below) 3. Date of Earliest Transaction (Month/Day/Year) 05/24/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock (1) | 05/24/2022 | S (2) | 1,996 | D | $ 35.53 | 12,381 | D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Explanation of Responses: 1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. 2. All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Remarks: /s/ S. Scott Lieberman, Attorney-in-fact | 05/25/2022 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_EBS_4_filed2022-05-25_0001367644-22-000077.xml
- Size
- 15,278 bytes
- SHA-256
- bca7750f0ee904cfec54decbd443189a338f31ae5c044a32f7040a7bc7e0bbca
- Original
- www.sec.gov